Journal article · 2020 · Open access

Patient familiarity with, understanding of, and preferences for clinical trial endpoints and terminology

Mitchell S. von Itzstein, Elda Railey, Mary L. Smith, Carol B. White, George W. Sledge, John R. Howell, Wendy Lawton, Donna M. Marinucci, Nisha G Unni, David E. Gerber

Cancer, 126(8), 1605–1613 · Published 22 January 2020 · DOI 10.1002/cncr.32730

Open PDFView at the publisherCite this paper

In brief

“Patient familiarity with, understanding of, and preferences for clinical trial endpoints and terminology” is a 2020 journal article by Mitchell S. von Itzstein and 9 co-authors, published in Cancer. OpenAlex counts 17 citations as of 22 November 2026, which puts it in the top 8% of works published in 2020 by citations. It is open access: the full text is free to read at Cancer.

Citations
17
Most cited in
2024 (4)
Field-weighted impact
1.29
References
44
Authors
10

Abstract

BACKGROUND: Although there is increased attention to designing and explaining clinical trials in ways that are clinically meaningful for patients, there is limited information on patient preferences, understanding, and perceptions of this content. METHODS: Maximum difference scaling (MaxDiff) methodology was used to develop a survey for assessing patients' understanding of 19 clinical terms and perceived importance of 9 endpoint surrogate phrases used in clinical trials and consent forms. The survey was administered electronically to individuals with metastatic breast cancer affiliated with the Metastatic Breast Cancer Alliance. Analyses were performed using Bayesian P values with statistical software. RESULTS: Among 503 respondents, 77% had a college degree, 70% were diagnosed with metastatic disease ≥2 years before survey completion, and 77% had received ≥2 lines of systemic therapy. Less than 35% of respondents reported understanding "fairly well" the terms symptomatic progression, duration of disease control, time to treatment cessation, and endpoints. Income level and time since onset of metastatic disease correlated with comprehension. Patients who had received ≥6 lines of therapy perceived that time until serious side effects (P < .001) and time on therapy (P < .001) were more important compared with those who had received only 1 line of therapy. Positively phrased parameters were associated with increased perceived importance. CONCLUSIONS: Even among educated, heavily pretreated patients, many commonly used clinical research terms are poorly understood. Comprehension and the perceived importance of trial endpoints vary over the course of disease. These observations may inform the design, discussion, and reporting of clinical trials.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

von Itzstein, M. S., Railey, E., Smith, M. L., White, C. B., Sledge, G. W., Howell, J. R., Lawton, W., Marinucci, D. M., Unni, N. G., & Gerber, D. E. (2020). Patient familiarity with, understanding of, and preferences for clinical trial endpoints and terminology. Cancer, 126(8), 1605–1613. https://doi.org/10.1002/cncr.32730

MLA 9

von Itzstein, Mitchell S., et al. “Patient familiarity with, understanding of, and preferences for clinical trial endpoints and terminology.” Cancer, vol. 126, no. 8, 2020, pp. 1605–1613. https://doi.org/10.1002/cncr.32730.

Chicago

von Itzstein, Mitchell S., Elda Railey, Mary L. Smith, Carol B. White, George W. Sledge, John R. Howell, Wendy Lawton, Donna M. Marinucci, Nisha G Unni, and David E. Gerber. 2020. “Patient familiarity with, understanding of, and preferences for clinical trial endpoints and terminology.” Cancer 126 (8): 1605–1613. https://doi.org/10.1002/cncr.32730.

Harvard

von Itzstein, M. S. et al. (2020) ‘Patient familiarity with, understanding of, and preferences for clinical trial endpoints and terminology’, Cancer, 126(8), pp. 1605–1613. doi:10.1002/cncr.32730.

IEEE

M. S. von Itzstein et al., “Patient familiarity with, understanding of, and preferences for clinical trial endpoints and terminology,” Cancer, vol. 126, no. 8, pp. 1605–1613, 2020, doi: 10.1002/cncr.32730.

BibTeX

@article{vonitzstein2020patient,
  title     = {{Patient familiarity with, understanding of, and preferences for clinical trial endpoints and terminology}},
  author    = {von Itzstein, Mitchell S. and Railey, Elda and Smith, Mary L. and White, Carol B. and Sledge, George W. and Howell, John R. and Lawton, Wendy and Marinucci, Donna M. and Unni, Nisha G and Gerber, David E.},
  journal   = {Cancer},
  year      = {2020},
  volume    = {126},
  number    = {8},
  pages     = {1605--1613},
  doi       = {10.1002/cncr.32730},
  url       = {https://doi.org/10.1002/cncr.32730}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202122
202233
202322
202444
202533
202633

Its field-weighted citation impact is 1.29: it has been cited 1.29 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Health Sciences › Health Professions › General Health Professions › Patient-Provider Communication in Healthcare

  • patient understanding
  • clinical trial endpoints
  • medical terminology
  • patient preferences
  • metastatic breast cancer
  • informed consent
  • surrogate endpoints
  • time on therapy

Work with this paper

Most-cited papers in Health Professions

All highly cited Health Professions papers

Questions about this paper

How do I cite this paper in APA style?

von Itzstein, M. S., Railey, E., Smith, M. L., White, C. B., Sledge, G. W., Howell, J. R., Lawton, W., Marinucci, D. M., Unni, N. G., & Gerber, D. E. (2020). Patient familiarity with, understanding of, and preferences for clinical trial endpoints and terminology. Cancer, 126(8), 1605–1613. https://doi.org/10.1002/cncr.32730

How many times has this paper been cited?

17 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Cancer: sign in and open the PDF from this page.

Who wrote this paper?

Mitchell S. von Itzstein, Elda Railey, Mary L. Smith, Carol B. White, George W. Sledge, John R. Howell, Wendy Lawton, Donna M. Marinucci, Nisha G Unni, David E. Gerber.

What is the DOI of this paper?

10.1002/cncr.32730, permanently at https://doi.org/10.1002/cncr.32730. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.